Covetrus Future Growth

Future criteria checks 4/6

Covetrus is forecast to grow earnings and revenue by 50.8% and 6.3% per annum respectively. EPS is expected to grow by 50.7% per annum. Return on equity is forecast to be 10.6% in 3 years.

Key information

50.8%

Earnings growth rate

50.7%

EPS growth rate

Healthcare earnings growth	20.6%
Revenue growth rate	6.3%
Future return on equity	10.6%
Analyst coverage	Low
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

XTRA:2NJ - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	5,385	100	125	N/A	4
12/31/2023	5,084	52	92	N/A	5
12/31/2022	4,795	10	112	N/A	5
6/30/2022	4,649	-13	2	60	N/A
3/31/2022	4,621	-40	70	126	N/A
12/31/2021	4,575	-54	42	102	N/A
9/30/2021	4,575	-56	44	104	N/A
6/30/2021	4,539	-90	-60	2	N/A
3/31/2021	4,376	-13	10	72	N/A
12/31/2020	4,339	-26	-5	53	N/A
9/30/2020	4,225	-19	31	80	N/A
6/30/2020	4,117	-940	112	154	N/A
3/31/2020	4,100	-996	18	58	N/A
12/31/2019	3,976	-980	64	103	N/A
9/30/2019	3,871	-948	93	130	N/A
6/30/2019	3,776	27	83	113	N/A
3/31/2019	3,772	65	131	157	N/A
12/29/2018	3,778	101	136	158	N/A
9/30/2018	3,791	69	74	94	N/A
6/30/2018	3,776	74	103	127	N/A
3/31/2018	3,649	67	42	64	N/A
12/30/2017	3,580	64	87	108	N/A
12/31/2016	3,353	70	92	105	N/A
12/26/2015	2,978	60	N/A	96	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2NJ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.03%).

Earnings vs Market: 2NJ is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 2NJ is expected to become profitable in the next 3 years.

Revenue vs Market: 2NJ's revenue (6.3% per year) is forecast to grow faster than the German market (4.6% per year).

High Growth Revenue: 2NJ's revenue (6.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2NJ's Return on Equity is forecast to be low in 3 years time (10.6%).

Covetrus Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Recent updates

Covetrus, Inc. Announces Executive Appointments

Covetrus® Expands Role and Responsibilities for Dr. Link Welborn, Chief Veterinary Officer

Covetrus to Showcase Its Vetsuite Solution At VMX 2024

Covetrus Announces Management Changes

Covetrus, Inc. Files Form 15

Covetrus, Inc.(NasdaqGS:CVET) dropped from NASDAQ Composite Index

Covetrus Announces the Appointment of Michelle Bonfilio as Chief People Officer

Covetrus Appoints Margie B. Pritchard as General Counsel and Corporate Secretary

Covetrus, Inc. Announces Retirement of Matthew Foulston as Executive Vice President, Effective December 31, 2022

Saxena White P.A. Announces Settlement of Class Action on Behalf of Purchasers of Covetrus, Inc. Common Stock

Second quarter 2022 earnings released: US$0.029 loss per share (vs US$0.23 loss in 2Q 2021)

Covetrus, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Independent Director recently sold €674k worth of stock

Clayton, Dubilier & Rice, LLC and TPG Global, LLC offered to acquire remaining 75.8% stake in Covetrus, Inc. (NasdaqGS:CVET) $2.2 billion.

First quarter 2022 earnings released: US$0.014 loss per share (vs US$0.12 loss in 1Q 2021)

Covetrus® Introduces Innovative Cloud-Based Practice Management Software for Veterinarians in the United Kingdom, EMEA and Asia Pacific

Covetrus, Inc. to Report Q1, 2022 Results on May 05, 2022

Covetrus, Inc., Annual General Meeting, May 11, 2022

High number of new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Covetrus, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Covetrus, Inc. Announces the Launch of Covetrus Pulse

Third quarter 2021 earnings released: US$0.029 loss per share (vs US$0.34 loss in 3Q 2020)

VP, Chief Accounting Officer & Global Controller Laura Phillips has left the company

Director recently bought €99k worth of stock

Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.41 profit in 2Q 2020)

Covetrus, Inc. (NasdaqGS:CVET) entered into a definitive agreement to acquire VCP.

Covetrus Enhances to Their Practice Management Software to Help Veterinary Clinics Compete Online and Deliver More Complete Healthcare

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.26 loss in 1Q 2020)

Independent Director recently sold €171k worth of stock

Covetrus, Inc. Announces the Addition of Stacey M.M. Shirra as Vice President of Global Talent Management

Revenue beats expectations

Full year 2020 earnings released: US$0.16 loss per share (vs US$9.52 loss in FY 2019)

Covetrus Appoints Link Welborn as Chief Veterinary Officer

Covetrus, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Covetrus Appoints Deborah Sharkey as Chief Consumer Officer

Covetrus, Inc.(NasdaqGS:CVET) dropped from Russell 1000 Growth-Defensive Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies